Abstract:Rationale: Pulmonary fibrosis is a chronic progressive lung disease with limited therapeutic options. We previously revealed that there is iron deposition in alveolar epithelial type II cell (AECII) in pulmonary fibrosis, which can be prevented by the iron chelator deferoxamine. However, iron in the cytoplasm and the mitochondria has two relatively independent roles and regulatory systems. In this study, we aimed to investigate the role of mitochondrial iron deposition in AECII injury and pulmonary fibrosis, and to find potential therapeutic strategies. Methods: BLM-treated mice, MLE-12 cells, and primary AECII were employed to establish the mouse pulmonary fibrosis model and epithelial cells injury model, respectively. Mitochondrial transplantation, siRNA and plasmid transfection, western blotting (WB), quantitative real-time polymerase chain reaction (RT-qPCR), polymerase chain reaction (PCR), immunofluorescence, immunoprecipitation (IP), MitoSOX staining, JC-1 staining, oxygen consumption rate (OCR) measurement, and Cell Counting Kit-8 (CCK8) assay were utilized to elucidate the role of mitochondrial iron deposition in cell and lung fibrosis and determine its mechanism. Results: This study showed that prominent mitochondrial iron deposition occurs within AECII in bleomycin (BLM)-induced pulmonary fibrosis mouse model and in BLM-treated MLE-12 epithelial cells. Further, the study revealed that healthy mitochondria rescue BLM-damaged AECII mitochondrial iron deposition and cell damage loss. Mitoferrin-2 (MFRN2) is the main transporter that regulates mitochondrial iron metabolism by transferring cytosolic iron into mitochondria, which is upregulated in BLM-treated MLE-12 epithelial cells. Direct overexpression of MFRN2 causes mitochondrial iron deposition and cell damage. In this study, decreased ubiquitination of the ubiquitin ligase F-box/LRR-repeat protein 5 (FBXL5) degraded iron-reactive element-binding protein 2 (IREB2) and promoted MFRN2 expression as well as mitochondrial iron deposition in damaged AECII. Activation of the prostaglandin E2 receptor EP4 subtype (EP4) receptor signaling pathway counteracted mitochondrial iron deposition by downregulating IREB2-MFRN2 signaling through upregulation of FBXL5. This intervention not only reduced mitochondrial iron content but also preserved mitochondrial function and protected against AECII damage after BLM treatment. Conclusion: Our findings highlight the unexplored roles, mechanisms, and regulatory approaches of abnormal mitochondrial iron metabolism of AECII in pulmonary fibrosis. Therefore, this study deepens the understanding of the mechanisms underlying pulmonary fibrosis and offers a promising strategy for developing effective therapeutic interventions using the EP4 receptor activator.

Mice Alveolar Epithelial Cells Phenotype Changed by Nmda Receptors Activation

NMDA Receptor Activation Induces Damage of Alveolar Type II Cells and Lung Fibrogenesis Through Ferroptosis

NMDA receptor activation induces damage of alveolar type II cells and lung fibrogenesis through ferroptosis(vol 1870, 119535, 2023)

NMDA Receptor-mediated CaMKII/ERK Activation Contributes to Renal Fibrosis

Role of Soluble Receptor for Advanced Glycation End Products on Bleomycin-Induced Lung Fibrosis in Mice

Effect of Alendronate Sodium on the Expression of Mesenchymal-Epithelial Transition Markers in Mice with Liver Fibrosis

NMDA Receptor Activation Inhibits the Protective Effect of BM‑MSCs on Bleomycin‑induced Lung Epithelial Cell Damage by Inhibiting ERK Signaling and the Paracrine Factor HGF.

The Excitotoxity of NMDA Receptor NR2D Subtype Mediates Human Fetal Lung Fibroblasts Proliferation and Collagen Production

NLRP3 participates in the regulation of EMT in bleomycin-induced pulmonary fibrosis

Ligand‐independent Transforming Growth Factor‐β Type I Receptor Signalling Mediates Type I Collagen‐induced Epithelial–mesenchymal Transition

N-methyl-D-aspartate receptor blockers attenuate bleomycin-induced pulmonary fibrosis by inhibiting endogenous mesenchymal stem cells senescence

Attenuation of Ventilation-Enhanced Epithelial–Mesenchymal Transition through the Phosphoinositide 3-Kinase-γ in a Murine Bleomycin-Induced Acute Lung Injury Model

Detection of epithelial to mesenchymal transition in airways of a bleomycin induced pulmonary fibrosis model derived from an α-smooth muscle actin-Cre transgenic mouse

Inhibitory Effects of Msfgfr2c on the Epithelial-to-mesenchymal Transition of AE2 Cells in Pulmonary Fibrosis.

N-Methyl-D-Aspartate Receptor Activation Mediates Lung Fibroblast Proliferation and Differentiation in Hyperoxia- Induced Chronic Lung Disease in Newborn Rats

Roles of p38 MAPK and JNK in TGF-β1-induced alveolar epithelial to mesenchymal transition

Abnormal mitochondrial iron metabolism damages alveolar type II epithelial cells involved in bleomycin-induced pulmonary fibrosis

Metabolic Characterization and RNA Profiling Reveal Glycolytic Dependence of Profibrotic Phenotype of Alveolar Macrophages in Lung Fibrosis

NMDA Receptor Activation Inhibits the Antifibrotic Effect of BM-MSCs on Bleomycin-Induced Pulmonary Fibrosis

Mitochondrial peptides cause proinflammatory responses in the alveolar epithelium via FPR-1, MAPKs, and AKT: a potential mechanism involved in acute lung injury.